免疫介导的血小板减少症的方方面面:免疫生物学和免疫疗法原理

IF 6.9 2区 医学 Q1 HEMATOLOGY
Thomas Moulinet , Anthony Moussu , Ludovic Pierson , Simona Pagliuca
{"title":"免疫介导的血小板减少症的方方面面:免疫生物学和免疫疗法原理","authors":"Thomas Moulinet ,&nbsp;Anthony Moussu ,&nbsp;Ludovic Pierson ,&nbsp;Simona Pagliuca","doi":"10.1016/j.blre.2023.101141","DOIUrl":null,"url":null,"abstract":"<div><p>Immune thrombocytopenia (ITP) is a rare autoimmune condition, due to peripheral platelet destruction through antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, cytotoxic T lymphocyte-mediated cytotoxicity, and megakaryopoiesis alteration. This condition may be idiopathic or triggered by drugs, vaccines, infections, cancers, autoimmune disorders and systemic diseases. Recent advances in our understanding of ITP immunobiology support the idea that other forms of thrombocytopenia, for instance, occurring after immunotherapy or cellular therapies, may share a common pathophysiology with possible therapeutic implications. If a decent pipeline of old and new agents is currently deployed for classical ITP, in other more complex immune-mediated thrombocytopenic disorders, clinical management is less harmonized and would deserve further prospective investigations.</p><p>Here, we seek to provide a fresh overview of pathophysiology and current therapeutical algorithms for adult patients affected by this disorder with specific insights into poorly codified scenarios, including refractory ITP and post-immunotherapy/cellular therapy immune-mediated thrombocytopenia.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"63 ","pages":"Article 101141"},"PeriodicalIF":6.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0268960X23001029/pdfft?md5=d28554e463885c9464a1f9b69e42d847&pid=1-s2.0-S0268960X23001029-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy\",\"authors\":\"Thomas Moulinet ,&nbsp;Anthony Moussu ,&nbsp;Ludovic Pierson ,&nbsp;Simona Pagliuca\",\"doi\":\"10.1016/j.blre.2023.101141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Immune thrombocytopenia (ITP) is a rare autoimmune condition, due to peripheral platelet destruction through antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, cytotoxic T lymphocyte-mediated cytotoxicity, and megakaryopoiesis alteration. This condition may be idiopathic or triggered by drugs, vaccines, infections, cancers, autoimmune disorders and systemic diseases. Recent advances in our understanding of ITP immunobiology support the idea that other forms of thrombocytopenia, for instance, occurring after immunotherapy or cellular therapies, may share a common pathophysiology with possible therapeutic implications. If a decent pipeline of old and new agents is currently deployed for classical ITP, in other more complex immune-mediated thrombocytopenic disorders, clinical management is less harmonized and would deserve further prospective investigations.</p><p>Here, we seek to provide a fresh overview of pathophysiology and current therapeutical algorithms for adult patients affected by this disorder with specific insights into poorly codified scenarios, including refractory ITP and post-immunotherapy/cellular therapy immune-mediated thrombocytopenia.</p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":\"63 \",\"pages\":\"Article 101141\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23001029/pdfft?md5=d28554e463885c9464a1f9b69e42d847&pid=1-s2.0-S0268960X23001029-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23001029\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23001029","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

免疫性血小板减少症(ITP)是一种罕见的自身免疫性疾病,是由于抗体依赖性细胞吞噬、补体依赖性细胞毒性、细胞毒性 T 淋巴细胞介导的细胞毒性和巨核细胞生成改变导致外周血小板破坏所致。这种疾病可能是特发性的,也可能由药物、疫苗、感染、癌症、自身免疫性疾病和全身性疾病引发。最近,我们对 ITP 免疫生物学的认识取得了进展,这支持了一种观点,即其他形式的血小板减少症,例如免疫疗法或细胞疗法后出现的血小板减少症,可能具有共同的病理生理学,并可能具有治疗意义。如果说传统的 ITP 目前采用了一系列新旧药物,那么对于其他更为复杂的免疫介导血小板减少症,临床管理则不太协调,值得进一步进行前瞻性研究。在此,我们试图对病理生理学和当前治疗算法进行新的概述,以帮助受这种疾病影响的成年患者了解包括难治性 ITP 和免疫疗法/细胞疗法后免疫介导血小板减少症在内的编码不清的情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy

Immune thrombocytopenia (ITP) is a rare autoimmune condition, due to peripheral platelet destruction through antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, cytotoxic T lymphocyte-mediated cytotoxicity, and megakaryopoiesis alteration. This condition may be idiopathic or triggered by drugs, vaccines, infections, cancers, autoimmune disorders and systemic diseases. Recent advances in our understanding of ITP immunobiology support the idea that other forms of thrombocytopenia, for instance, occurring after immunotherapy or cellular therapies, may share a common pathophysiology with possible therapeutic implications. If a decent pipeline of old and new agents is currently deployed for classical ITP, in other more complex immune-mediated thrombocytopenic disorders, clinical management is less harmonized and would deserve further prospective investigations.

Here, we seek to provide a fresh overview of pathophysiology and current therapeutical algorithms for adult patients affected by this disorder with specific insights into poorly codified scenarios, including refractory ITP and post-immunotherapy/cellular therapy immune-mediated thrombocytopenia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信